Therapeutic Antibody Development for Liver Disease

Ace Therapeutics is an expert in the field of liver disease research. Based on our extensive research experience and advanced technology platform, we aim to provide the most specialized research services to developers of therapeutic antibodies targeting liver disease worldwide.

Introduction to Therapeutic Antibodies for Liver Disease

Antibodies, especially monoclonal antibodies, are characterized by high specificity, high affinity, and remarkable potency. These advantages allow them to show advantages unmatched by other types of drugs. The discovery of therapeutic antibodies has solved some of the hard-to-tackle diseases. In the field of liver disease, antibodies have also demonstrated unique superiority.

Figure 1. Anti-CCL24 antibody alleviates liver fibrosis and inflammation in the MCD-diet-induced mouse model. (Segal-Salto M., et al. 2020)

What Can We Do?

• Target Screening

• Identification and validation of novel therapeutic targets: Utilize cutting-edge technologies, including genomics, proteomics, and bioinformatics, to identify promising targets specifically implicated in the pathogenesis of various liver diseases.
• Analysis of target expression and function: Investigate the expression patterns and functional roles of potential targets in both healthy and diseased liver tissues, ensuring the selection of targets with high therapeutic relevance.
• Development of robust target validation assays: Establish reliable in vitro and in vivo assays to validate the therapeutic potential of selected targets, confirming their role in disease progression and their suitability for antibody targeting.

• Antibody Screening and Optimization

• Generation of diverse antibody libraries: Employ advanced antibody engineering technologies, including phage display, yeast display, and hybridoma technology, to generate large and diverse antibody libraries against validated targets.
• High-throughput screening for lead antibody candidates: Utilize sophisticated screening platforms to identify antibodies with high affinity, specificity, and desired functional characteristics, such as blocking or activating specific pathways.
• Immunogenicity assessment: Perform in vitro T-cell activation assays to assess the potential for antibody candidates to elicit unwanted immune responses and conduct in vivo studies in appropriate animal models to evaluate the immunogenicity and safety profile of lead antibody candidates.
• Lead antibody optimization and characterization: Employ affinity maturation and other optimization techniques to enhance the binding properties, stability, and developability of lead antibody candidates. Rigorous characterization studies are performed to assess their biophysical and biochemical properties.

• Therapeutic Effect Assessment

• Development of relevant in vitro and in vivo disease models: Customize in vitro and in vivo models of liver disease, including cell-based assays, animal models of liver fibrosis, and models of viral hepatitis, to evaluate the therapeutic efficacy of antibody candidates.
• Assessment of antibody efficacy: Employ a range of endpoints, including biochemical markers, histological analysis, and imaging techniques, to assess the therapeutic impact of antibody treatment on disease progression and liver function.

Ace Therapeutics has extensive research experience in the field of therapeutic antibody development. With years of research experience, our scientists have integrated therapeutic antibodies and liver disease treatment and have established perfect therapeutic antibody development services for liver disease. If you would like to learn more about our services, please feel free to contact us.

Reference

1. Segal-Salto M., et al. A blocking monoclonal antibody to CCL24 alleviates liver fibrosis and inflammation in experimental models of liver damage. JHEP Rep. 2020 Jan 2;2(1):100064.

Our products and services are for research use only and can not be used for diagnostic or other purposes.